Home › Kanser sa Suso
Pag-aaral pangklinika para sa Kanser sa Suso na nagre-recruit sa U.S.
670 pag-aaral para sa Kanser sa Suso ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- New York City, NY144 pag-aaral
- Houston, TX126 pag-aaral
- Boston, MA110 pag-aaral
- Nashville, TN78 pag-aaral
- Los Angeles, CA73 pag-aaral
- Edison, NJ70 pag-aaral
- Queens, NY67 pag-aaral
- Durham, NC63 pag-aaral
- St. Louis, MO63 pag-aaral
- Chicago, IL59 pag-aaral
- Dallas, TX54 pag-aaral
- Philadelphia, PA51 pag-aaral
- Arlington, VA50 pag-aaral
- Greenburgh, NY45 pag-aaral
- San Antonio, TX45 pag-aaral
- Washington, DC44 pag-aaral
- Baltimore, MD44 pag-aaral
- Staten Island, NY43 pag-aaral
- Baldwin Park, CA43 pag-aaral
- Miami, FL42 pag-aaral
- Pittsburgh, PA42 pag-aaral
- Atlanta, GA42 pag-aaral
- New Rochelle, NY41 pag-aaral
- San Diego, CA41 pag-aaral
- San Francisco, CA40 pag-aaral
- Tampa, FL40 pag-aaral
- Columbus, OH39 pag-aaral
- Rochester, MN39 pag-aaral
- East Norwalk, CT38 pag-aaral
- Jacksonville, FL38 pag-aaral
- New Haven, CT38 pag-aaral
- Seattle, WA37 pag-aaral
- Kansas City, MO34 pag-aaral
- Detroit, MI34 pag-aaral
- Portland, OR33 pag-aaral
- Cleveland, OH33 pag-aaral
- Aurora, CO30 pag-aaral
- Santa Monica, CA29 pag-aaral
- Mountain View, CA27 pag-aaral
- Salt Lake City, UT27 pag-aaral
Ayos sa estado
- Alabama32 pag-aaral
- Alaska8 pag-aaral
- Arizona55 pag-aaral
- Arkansas17 pag-aaral
- California180 pag-aaral
- Colorado56 pag-aaral
- Connecticut50 pag-aaral
- Delaware9 pag-aaral
- District of Columbia27 pag-aaral
- Florida144 pag-aaral
- Georgia52 pag-aaral
- Hawaii11 pag-aaral
- Idaho7 pag-aaral
- Illinois81 pag-aaral
- Indiana31 pag-aaral
- Iowa23 pag-aaral
- Kansas26 pag-aaral
- Kentucky23 pag-aaral
- Louisiana21 pag-aaral
- Maine16 pag-aaral
- Maryland65 pag-aaral
- Massachusetts116 pag-aaral
- Michigan72 pag-aaral
- Minnesota64 pag-aaral
- Mississippi9 pag-aaral
- Missouri73 pag-aaral
- Montana13 pag-aaral
- Nebraska26 pag-aaral
- Nevada22 pag-aaral
- New Hampshire18 pag-aaral
- New Jersey94 pag-aaral
- New Mexico20 pag-aaral
- New York184 pag-aaral
- North Carolina91 pag-aaral
- North Dakota9 pag-aaral
- Ohio77 pag-aaral
- Oklahoma20 pag-aaral
- Oregon41 pag-aaral
- Pennsylvania91 pag-aaral
- Rhode Island12 pag-aaral
- South Carolina22 pag-aaral
- South Dakota17 pag-aaral
- Tennessee90 pag-aaral
- Texas176 pag-aaral
- Utah42 pag-aaral
- Vermont5 pag-aaral
- Virginia84 pag-aaral
- Washington50 pag-aaral
- West Virginia14 pag-aaral
- Wisconsin44 pag-aaral
- Wyoming3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
WashU DIEP Flap Video and Patient Understanding Improvement
Nagre-recruit
Edad 18 pataas · Kababaihan · Na-update Nob 13, 2026 · NCT06864754Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07619534Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07360314A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07748208Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT05696626PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07069595A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT05894239A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Nagre-recruitPhase 1
Edad 18 hanggang 55 · Kababaihan · Na-update Nob 12, 2026 · NCT07310420Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
Nagre-recruit
Edad 18 pataas · Kababaihan · Na-update Nob 12, 2026 · NCT05649072Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06797635Multi-center MRD Registry for Inflammatory Breast Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06966050A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07827573Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
Nagre-recruit
Edad 70 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07629206An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07222267A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Nagre-recruitPhase 3
Edad 18 pataas · Kababaihan · Na-update Nob 12, 2026 · NCT07541079BostonGene and Exigent Genomic INsight Study
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06272864Genomic Services Research Program
Nagre-recruitObservasyonal na pag-aaral
1 Month – 105 Years · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT02595957Utility of a Mobile Application for Young Women With Breast Cancer
Nagre-recruit
Edad 18 hanggang 45 · Kababaihan · Na-update Nob 12, 2026 · NCT07009093S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT03418961Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Nagre-recruitPhase 1
Edad 12 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT05372640Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Nagre-recruitPhase 2
Edad 18 hanggang 72 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT01174121Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Nagre-recruitPhase 1/2
Lahat ng edad · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT06590857Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
Nagre-recruit
Edad 18 hanggang 80 · Kababaihan · Na-update Nob 12, 2026 · NCT05245812A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07905001Pilot Study of Hydroxychloroquine for the Treatment of AIMSS
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT07825454Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.